Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | SPR | P35270 | 1/20 | 0.39 |
| ▸ | VNN1 | O95497 | 8/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | CCR5 | P51681 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3772615 | 1.00 | LRRK2 (0.41) | LRRK2NAMPTSPRVNN1HSD11B1 | |
| SCHEMBL3772617 | 0.87 | LRRK2 (0.48) | LRRK2SPRHSD11B1ALDH1A1 | |
| SCHEMBL3777344 | 0.84 | LRRK2 (0.46) | LRRK2 | |
| SCHEMBL3767028 | 0.83 | LRRK2 (0.47) | LRRK2ALDH1A1PDE10A | |
| SCHEMBL10225283 | 0.83 | LRRK2 (0.49) | LRRK2 | |
| SCHEMBL13006057 | 0.82 | LRRK2 (0.45) | LRRK2 | |
| SCHEMBL3775077 | 0.82 | LRRK2 (0.48) | LRRK2 | |
| SCHEMBL883223 | 0.82 | LRRK2 (0.55) | LRRK2NAMPTALDH1A1HTT | |
| SCHEMBL3772259 | 0.79 | SMN1; SMN2 (0.44) | LRRK2NPC1RAB9AALDH1A1HTT | |
| SCHEMBL3783202 | 0.79 | LRRK2 (0.51) | LRRK2NPC1RAB9AALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170320870-A1 | COMPOUNDS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2017-11-09 | — | — | US | disclosed |
| EP-2408772-B1 | COMPOUNDS | MEDICAL RES COUNCIL TECHNOLOGY (GB) | 2015-07-01 | — | — | EP | disclosed |
| US-20100317646-A1 | COMPOUNDS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170320870-A1 | COMPOUNDS | CBR3, CNR1, HCAR3 | LRRK2 2309/4885NAMPT 1960/4885SPR 2994/4885 |
| US-20100317646-A1 | COMPOUNDS | CBR3, CNR1, HCAR3 | LRRK2 2208/4885NAMPT 2020/4885SPR 3035/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.